Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Disruption of a -35 kb Enhancer Impairs CTCF Binding and MLH1 Expression in Colorectal Cells.

Liu Q, Thoms JAI, Nunez AC, Huang Y, Knezevic K, Packham D, Poulos RC, Williams R, Beck D, Hawkins NJ, Ward RL, Wong JWH, Hesson LB, Sloane MA, Pimanda JE.

Clin Cancer Res. 2018 Sep 15;24(18):4602-4611. doi: 10.1158/1078-0432.CCR-17-3678. Epub 2018 Jun 13.

PMID:
29898989
2.

AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo.

Unnikrishnan A, Vo ANQ, Pickford R, Raftery MJ, Nunez AC, Verma A, Hesson LB, Pimanda JE.

Leukemia. 2018 Apr;32(4):900-910. doi: 10.1038/leu.2017.340. Epub 2017 Nov 29.

3.

Pathogenic germline MCM9 variants are rare in Australian Lynch-like syndrome patients.

Liu Q, Hesson LB, Nunez AC, Packham D, Hawkins NJ, Ward RL, Sloane MA.

Cancer Genet. 2016 Nov;209(11):497-500. doi: 10.1016/j.cancergen.2016.10.001. Epub 2016 Oct 11.

PMID:
27886675
4.

Integrated Genetic, Epigenetic, and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumors.

Hesson LB, Ng B, Zarzour P, Srivastava S, Kwok CT, Packham D, Nunez AC, Beck D, Ryan R, Dower A, Ford CE, Pimanda JE, Sloane MA, Hawkins NJ, Bourke MJ, Wong JW, Ward RL.

Mol Cancer Res. 2016 Dec;14(12):1217-1228. Epub 2016 Sep 26.

5.

PDGF-AB and 5-Azacytidine induce conversion of somatic cells into tissue-regenerative multipotent stem cells.

Chandrakanthan V, Yeola A, Kwan JC, Oliver RA, Qiao Q, Kang YC, Zarzour P, Beck D, Boelen L, Unnikrishnan A, Villanueva JE, Nunez AC, Knezevic K, Palu C, Nasrallah R, Carnell M, Macmillan A, Whan R, Yu Y, Hardy P, Grey ST, Gladbach A, Delerue F, Ittner L, Mobbs R, Walkley CR, Purton LE, Ward RL, Wong JW, Hesson LB, Walsh W, Pimanda JE.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):E2306-15. doi: 10.1073/pnas.1518244113. Epub 2016 Apr 4.

6.

A cryptic paracentric inversion of MSH2 exons 2-6 causes Lynch syndrome.

Liu Q, Hesson LB, Nunez AC, Packham D, Williams R, Ward RL, Sloane MA.

Carcinogenesis. 2016 Jan;37(1):10-17. doi: 10.1093/carcin/bgv154. Epub 2015 Oct 24.

PMID:
26498247
7.

Mosaic Epigenetic Inheritance as a Cause of Early-Onset Colorectal Cancer.

Sloane MA, Nunez AC, Packham D, Kwok CT, Suthers G, Hesson LB, Ward RL.

JAMA Oncol. 2015 Oct;1(7):953-7. doi: 10.1001/jamaoncol.2015.1484.

PMID:
26181641
8.

Lynch syndrome associated with two MLH1 promoter variants and allelic imbalance of MLH1 expression.

Hesson LB, Packham D, Kwok CT, Nunez AC, Ng B, Schmidt C, Fields M, Wong JW, Sloane MA, Ward RL.

Hum Mutat. 2015 Jun;36(6):622-30. doi: 10.1002/humu.22785. Epub 2015 Apr 17.

9.

Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients.

Sloane MA, Hesson LB, Nunez AC, Thompson BA, Ward RL.

Clin Epigenetics. 2014 Dec 13;6(1):32. doi: 10.1186/s13148-014-0032-6. eCollection 2014.

10.

Altered promoter nucleosome positioning is an early event in gene silencing.

Hesson LB, Sloane MA, Wong JW, Nunez AC, Srivastava S, Ng B, Hawkins NJ, Bourke MJ, Ward RL.

Epigenetics. 2014 Oct;9(10):1422-30. doi: 10.4161/15592294.2014.970077.

11.

Epigenetic inactivation of the candidate tumor suppressor USP44 is a frequent and early event in colorectal neoplasia.

Sloane MA, Wong JW, Perera D, Nunez AC, Pimanda JE, Hawkins NJ, Sieber OM, Bourke MJ, Hesson LB, Ward RL.

Epigenetics. 2014 Aug;9(8):1092-100. doi: 10.4161/epi.29222. Epub 2014 May 16.

12.

Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure.

Hesson LB, Patil V, Sloane MA, Nunez AC, Liu J, Pimanda JE, Ward RL.

PLoS Genet. 2013;9(7):e1003636. doi: 10.1371/journal.pgen.1003636. Epub 2013 Jul 25.

13.

iTRAQ-based proteomic profiling of breast cancer cell response to doxorubicin and TRAIL.

Leong S, Nunez AC, Lin MZ, Crossett B, Christopherson RI, Baxter RC.

J Proteome Res. 2012 Jul 6;11(7):3561-72. doi: 10.1021/pr2012335. Epub 2012 Jun 7.

PMID:
22587632
14.

Serum albumin prevents protein aggregation and amyloid formation and retains chaperone-like activity in the presence of physiological ligands.

Finn TE, Nunez AC, Sunde M, Easterbrook-Smith SB.

J Biol Chem. 2012 Jun 15;287(25):21530-40. doi: 10.1074/jbc.M112.372961. Epub 2012 May 1.

15.

[Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events].

Díaz CJ, Núñez AC, Flores MI, Arcaute HD, Archondo T.

Arch Cardiol Mex. 2006 Oct-Dec;76(4):366-75. Spanish.

PMID:
17315612

Supplemental Content

Loading ...
Support Center